bioAffinity Technologies, Inc. — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
bioAffinity Technologies announced 235 CyPath Lung tests performed in October 2026, a 29% increase versus October 2025 and equivalent to 45% of Q3 2026's total quarterly volume. The company cited expanded sales team, physician adoption growth, and R&D advances into asthma and COPD applications. No revenue, reimbursement rates, or financial impact figures were disclosed.
Why this rating
Strong monthly test growth is operationally encouraging for a $22.6M market-cap diagnostic company, but lacks revenue translation or margin data. Single-month volume metrics carry execution risk absent reimbursement/profitability visibility.
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.